Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
The purpose of this prospective, longitudinal, noninterventional study is to describe
 clinical characteristics, evolution of disease burden, and treatment patterns in patients
 with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).
Inclusion Criteria:

 -  MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR
 intermediate-1 risk by DIPSS by reason of age alone.

 -  ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR
 currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon,
 busulfan, ruxolitinib, etc).

 -  Willing and able to provide written informed consent.

 -  Willing and able to complete patient assessment questionnaires either alone or with
 minimal assistance from a caregiver and/or trained site personnel.

 -  Under the supervision of a physician for the current care of MF or ET.

 Exclusion Criteria:

 -  Individuals who are participating in blinded investigational drug studies.

 -  Individuals who are participating in Incyte investigational/interventional drug trials
 (company- or investigator-sponsored studies) until they have completed the 30-day end
 of study visit.

 -  Life expectancy ≤ 6 months.

 -  Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic
 myelogenous leukemia, or secondary thrombocytosis.